These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Recent advances in the investigation of lipoprotein metabolism using tracer methodology. Chan DC; Watts GF Clin Lab; 2006; 52(7-8):353-61. PubMed ID: 16955633 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein transport in the metabolic syndrome: methodological aspects of stable isotope kinetic studies. Chan DC; Barrett PH; Watts GF Clin Sci (Lond); 2004 Sep; 107(3):221-32. PubMed ID: 15225121 [TBL] [Abstract][Full Text] [Related]
4. Kinetic Studies to Elucidate Impaired Metabolism of Triglyceride-rich Lipoproteins in Humans. Adiels M; Mardinoglu A; Taskinen MR; Borén J Front Physiol; 2015; 6():342. PubMed ID: 26635628 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms for therapeutic correction of dyslipidaemia in insulin resistance and diabetes. Watts GF; Chan DC Atheroscler Suppl; 2010 Jun; 11(1):61-4. PubMed ID: 20452838 [TBL] [Abstract][Full Text] [Related]
6. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Chan DC; Watts GF Expert Opin Pharmacother; 2011 Jan; 12(1):13-30. PubMed ID: 20629587 [TBL] [Abstract][Full Text] [Related]
7. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Adiels M; Olofsson SO; Taskinen MR; Borén J Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848 [TBL] [Abstract][Full Text] [Related]
14. Lipoprotein transport in the metabolic syndrome: pathophysiological and interventional studies employing stable isotopy and modelling methods. Chan DC; Barrett PH; Watts GF Clin Sci (Lond); 2004 Sep; 107(3):233-49. PubMed ID: 15225143 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states. Chan DC; Watts GF Curr Vasc Pharmacol; 2008 Jan; 6(1):67-77. PubMed ID: 18220942 [TBL] [Abstract][Full Text] [Related]
16. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome. Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Watts GF; Ooi EM; Chan DC Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928 [TBL] [Abstract][Full Text] [Related]
18. Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Chan DC; Watts GF; Ng TW; Yamashita S; Barrett PH Eur J Clin Invest; 2008 Oct; 38(10):743-51. PubMed ID: 18837799 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA regulation of mitochondrial and ER stress signaling pathways: implications for lipoprotein metabolism in metabolic syndrome. Christian P; Su Q Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E729-37. PubMed ID: 25184990 [TBL] [Abstract][Full Text] [Related]
20. Nuclear magnetic resonance-determined lipoprotein abnormalities in nonhuman primates with the metabolic syndrome and type 2 diabetes mellitus. Ding SY; Tigno XT; Hansen BC Metabolism; 2007 Jun; 56(6):838-46. PubMed ID: 17512318 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]